EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors

Anna Pawłowska iD, Anna Rekowska iD, Weronika Kuryło iD, Anna Pańczyszyn, Jan Kotarski iD, Iwona Wertel iD

International Journal of Molecular Sciences · 29.06.2023 · 24 (13) · 10859

DOI: 10.3390/ijms241310859 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.06.2023. Verfasst von Anna Pawłowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Independent Laboratory of Cancer Diagnostics and Immunology, Department of Oncological Gynaecology and Gynaecology, Faculty of Medicine, Medical Univ…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Ovarian Neoplasms. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Medical University of Lublin, grant number DS124, and in part by National Science Centre, Poland, Preludium grant number 2021/41…, Medical University of Lublin, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The standard treatment of ovarian cancer (OC) patients, including debulking surgery and first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority (~70%) of patients with advanced OC. Clinical trials have shown only a modest (10–15%) response of OC individuals to treatment based on immune checkpoint inhibitors (ICIs). The resistance of OC to therapy is caused by various factors, including OC heterogeneity, low density of tumor-infiltrating lymphocytes (TILs), non-cellular and cellular interactions in the tumor microenvironment (TME), as well as a network of microRNA regulating immune checkpoint pathways. Moreover, ICIs are the most efficient in tumors that are marked by high microsatellite instability and high tumor mutation burden, which is rare among OC patients. The great challenge in ICI implementation is connected with distinguishing hyper-, pseudo-, and real progression of the disease. The understanding of the immunological, molecular, and genetic mechanisms of OC resistance is crucial to selecting the group of OC individuals in whom personalized treatment would be beneficial. In this review, we summarize current knowledge about the selected factors inducing OC resistance and discuss the future directions of ICI-based immunotherapy development for OC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsOvarian NeoplasmsHumansFemaleLymphocytes, Tumor-InfiltratingImmunotherapyCarcinoma, Ovarian EpithelialTumor Microenvironment

Stichwörter der Autor:innen

PD-1/PD-L1TIGITimmune checkpointsimmunotherapymicroRNAovarian cancerresistance

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Independent Laboratory of Cancer Diagnostics and Immunology, Department of Oncological Gynaecology and Gynaecology, Faculty of Medicine, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland.
  • Students' Scientific Association, Independent Laboratory of Cancer Diagnostics and Immunology, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland.
  • Institute of Medical Sciences, Department of Biology and Genetics, Faculty of Medicine, University of Opole, Oleska 48, 45-052 Opole, Poland.

ORCID-Profile: Anna Pawłowska, Anna Rekowska, Weronika Kuryło, Jan Kotarski, Iwona Wertel

Förderung

  • This work was supported by the Medical University of Lublin, grant number DS124, and in part by National Science Centre, Poland, Preludium grant number 2021/41…
  • Medical University of Lublin
  • National Science Centre, Poland

Zitieren

APA

Pawłowska, A., Rekowska, A., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023). Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 24(13), 10859. https://doi.org/10.3390/ijms241310859

Vancouver

Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, Kotarski J, Wertel I. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2023;24(13):10859. doi:10.3390/ijms241310859

BibTeX
@article{Pawowska2023,
  author = {Pawłowska, Anna and Rekowska, Anna and Kuryło, Weronika and Pańczyszyn, Anna and Kotarski, Jan and Wertel, Iwona},
  title = {Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {13},
  pages = {10859},
  doi = {10.3390/ijms241310859}
}
Kostenlos starten →